Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Effective ways to prevent arthropathy in severe hemophilia are unknown. METHODS: We randomly assigned young boys with severe hemophilia A to regular infusions of recombinant factor VIII (prophylaxis) or to an enhanced episodic infusion schedule of at least three doses totaling a minimum of 80 IU of factor VIII per kilogram of body weight at the time of a joint hemorrhage. The primary outcome was the incidence of bone or cartilage damage as detected in index joints (ankles, knees, and elbows) by radiography or magnetic resonance imaging (MRI). RESULTS: Sixty-five boys younger than 30 months of age were randomly assigned to prophylaxis (32 boys) or enhanced episodic therapy (33 boys). When the boys reached 6 years of age, 93% of those in the prophylaxis group and 55% of those in the episodic-therapy group were considered to have normal index-joint structure on MRI (P=0.006). The relative risk of MRI-detected joint damage with episodic therapy as compared with prophylaxis was 6.1 (95% confidence interval, 1.5 to 24.4). The mean annual numbers of joint and total hemorrhages were higher at study exit in the episodic-therapy group than in the prophylaxis group (P<0.001 for both comparisons). High titers of inhibitors of factor VIII developed in two boys who received prophylaxis; three boys in the episodic-therapy group had a life-threatening hemorrhage. Hospitalizations and infections associated with central-catheter placement did not differ significantly between the two groups. CONCLUSIONS: Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A. (ClinicalTrials.gov number, NCT00207597 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although effective, ERT is limited by an approximately 40% noncompliance rate, costs ≥$200,000 annually, and advances arthropathy.172, 173, 174, 175”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [172]
Citations
Cites
Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B
NILSSON, I. M., BERNTORP, E., LÖFQVIST, T., & PETTERSSON, H. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00546.x · Cited by 961
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
ALEDORT, L. M., HASCHMEYER, R. H., PETTERSSON, H., & THE ORTHOPAEDIC OUTCOME STUDY GROUP (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb00815.x · Cited by 611
A Radiologic Classification of Hemophilic Arthropathy
PETTERSSON, H., AHLBERG, Å., & NILSSON, I. M. (1980) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198006000-00018 · Cited by 549
Proceedings: A more uniform measurement of factor VIII inhibitors.
Ck, K., Aledort, L. M., Aronson, D. D., Counts, R., Edson, van Eys, J., Fratantoni, J. C., Green, D., Hampton, J., Hilgartner, M. W., et al. (1975) · PubMed · Cited by 346
Barriers to compliance with prophylaxis therapy in haemophilia
Hacker, M. R., Geraghty, S., & Manco-Johnson, M. (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00534.x · Cited by 261
Self-citationAhlberg, Å. (1965) · Acta Orthopaedica Scandinavica · doi:10.3109/ort.1965.36.suppl-77.01 · Cited by 252
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors
Soucie, J. M. (2004) · Blood · doi:10.1182/blood-2003-05-1457 · Cited by 244
Self-citationIorio, A., Marchesini, E., Marcucci, M., Stobart, K., & Chan, A. K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003429.pub4 · Cited by 192
Nuss, R., Kilcoyne, R. F., Geraghty, S., Shroyer, A. L. W., Rosky, J. W., Mawhinney, S., Wiedel, J., & Manco‐Johnson, M. (2000) · Haemophilia · doi:10.1046/j.1365-2516.2000.00383.x · Cited by 159
Self-citationLee, C. A., Kessler, C. M., Varon, D., Martinowitz, U. P., Heim, M., Kreuz, W., Escuriola‐Ettingshausen, C., Funk, M. J., SCHMIDT, H., & Kornhuber, B. (1998) · Haemophilia · doi:10.1046/j.1365-2516.1998.440413.x · Cited by 154
Research works printed but not linked: 5
- Robinson PM, 1967, Can Med Assoc J, 97, 559
- Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis. Medical bulletin #193. New York: National Hemophilia Foundation, March 11, 1994.
- Stobart K, 2006, Cochrane Database Syst Rev, 2, CD003429
- Kasper CK, 1975, Thromb Diath Haemorr, 34, 612
- Report on the Universal Data Collection Program. Atlanta: Centers for Disease Control and Prevention, 2005;7(1):28. (Accessed July 18, 2007, athttp://www.cdc.gov/ncbddd/hbd/documents/UDC7%281%29.pdf.)
Cited by
Items 601–700 of 1,000
Progression of haemophilic arthropathy in children: a Lithuanian – Danish comparative study
Trakymienė, S. Š., Clausen, N., Poulsen, L. H., INGERSLEV, J., & Ragelienė, L. (2012) · Haemophilia · doi:10.1111/hae.12058 · Cited by 24
Ragni, M. V. (2015) · Drugs · doi:10.1007/s40265-015-0451-5 · Cited by 25
“A recent randomized study demonstrated that every-other-day factor prophylaxis reduces joint bleeds and less joint damage [5], which has led to the adoption of prophylaxis as the standard of care for prevention of bleeds in severe hemophilia [6].”
BackgroundIannazzo, S., Cortesi, P. A., Crea, R., Steinitz, K. N., Mantovani, L. G., & Gringeri, A. (2016) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000610 · Cited by 24
Kumar, P., Gao, K., Wang, C., Pivetti, C. D., Lankford, L., Farmer, D. L., & Wang, A. (2018) · Cell Transplantation · doi:10.1177/0963689717728937 · Cited by 23
Common themes and challenges in hemophilia care: a multinational perspective
Stoffman, J. M., Andersson, N. G., Branchford, B. R., Batt, K., d’Oiron, R., Ettingshausen, C. E., Hart, D. P., Jiménez‐Yuste, V., Kavaklı, K., Mancuso, M. E., et al. (2018) · Hematology · doi:10.1080/10245332.2018.1505225 · Cited by 25
“evidence of effectiveness in the prevention of bleeding and joint destruction in patients with moderate and severe disease [2,33].”
BackgroundSimpson, M. L., Desai, V., Maro, G. S., & Yan, S. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.19318 · Cited by 24
Is on‐demand treatment effective in patients with severe haemophilia?
Aznar, J. A., Marco, A., Jiménez‐Yuste, V., Fernández-Fontecha, E. M., Pérez, R. M. Á., Soto, I., Parra, R., MORENO, M., Mingot‐Castellano, M. E., Moret, A., et al. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02806.x · Cited by 27
Functional independence score in hemophilia: A cross‐sectional study assessment of Mexican children
Tlacuilo‐Parra, A., Villela‐Rodriguez, J., Garibaldi‐Covarrubias, R., Soto‐Padilla, J., & Orozco-Alcalá, J. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22291 · Cited by 24
“A recent study demonstrated the efficacy of prophylactic versus episodic treatment in reducing the incidence of joint hemorrhages and lowering joint damage among children [6].”
BackgroundLjung, R. C. R. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24340 · Cited by 24
Emerging Therapies in Hemophilia: Improving Equitable Access to Care
Lewandowska, M., Nasr, S., & Shapiro, A. D. (2025) · Journal of Blood Medicine · doi:10.2147/jbm.s490588 · Cited by 34
Self-citationAdherence to clotting factors among persons with hemophilia A or B
Armstrong, E. P., Malone, D. C., Krishnan, S., & Wessler, M. J. (2014) · Hematology · doi:10.1179/1607845414y.0000000176 · Cited by 23
Zhang, H., Huang, J., Kong, X., Ma, G., & Fang, Y. (2019) · Health and Quality of Life Outcomes · doi:10.1186/s12955-019-1083-3 · Cited by 23
Andrawes, N. G., Fayek, M. H., Salah, N. Y., & Mostafa, R. A. (2019) · Haemophilia · doi:10.1111/hae.13917 · Cited by 23
Jonsson, F., Schmitt, C., Petry, C., Mercier, F., Frey, N., & Retout, S. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01006-0 · Cited by 24
Recombinant factor VIII Fc for the treatment of haemophilia A
Hermans, C. R. J. R., Mancuso, M. E., Nolan, B., & Pasi, J. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13610 · Cited by 27
Hemophilia A (Factor VIII Deficiency)
Seaman, C. D., Xavier, F., & Ragni, M. V. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.07.006 · Cited by 34
Wall, C., Xiang, H., Palmer, B., Chalmers, E. A., Chowdary, P., Collins, P. W., Fletcher, S. J., Hall, G. W., Hart, D. P., Mathias, M., et al. (2023) · Haemophilia · doi:10.1111/hae.14762 · Cited by 23
Biotribological and biomechanical changes after experimental haemarthrosis in the rabbit knee
Ravanbod, R., Torkaman, G., & Esteki, A. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02375.x · Cited by 23
Health economic models in hemophilia A and utility assumptions from a clinician's perspective
Valente, M., Cortesi, P. A., Lassandro, G., Mathew, P., Pocoski, J., Molinari, A. C., Mantovani, L. G., & Giordano, P. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25543 · Cited by 25
Self-citationPharmacokinetics of plasma‐derived vs. recombinant FVIII concentrates: a comparative study
Morfini, M., Marchesini, E., Paladino, E., Santoro, C., Zanon, E., & Iorio, A. (2014) · Haemophilia · doi:10.1111/hae.12550 · Cited by 23
Prophylaxis in real life scenarios
Fischer, K., Konkle, B. A., Broderick, C. R., & Kessler, C. M. (2014) · Haemophilia · doi:10.1111/hae.12425 · Cited by 23
Rationale for individualizing haemophilia care
Sørensen, B., Auerswald, G., Benson, G. M., Elezović, I. V., Felder, M., Lambert, T., Morfini, M., Remor, E., Salaj, P., Santagostino, E., et al. (2014) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000225 · Cited by 23
Controversies regarding the prophylactic management of adults with severe haemophilia A
Valentino, L. A. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.02159.x · Cited by 23
Self-citationHaemophilia prophylaxis: how can we justify the costs?
Feldman, B. M., Berger, K., Bohn, R. L., Carcao, M. D., Fischer, K., Gringeri, A., Hoots, K. W., Mantovani, L. G., Willan, A. R., & Schramm, W. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02790.x · Cited by 23
Clinical trial design in haemophilia
DiMichele, D., Blanchette, V. S., & Berntorp, E. E. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02824.x · Cited by 23
Self-citationModifiers of clinical phenotype in severe congenital hemophilia
Franchini, M., & Mannucci, P. M. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.05.038 · Cited by 27
Bakeer, N., & Shapiro, A. D. (2019) · F1000Research · doi:10.12688/f1000research.16039.1 · Cited by 23
Self-citationMerry Christmas for Patients with Hemophilia B
Ponder, K. P. (2011) · New England Journal of Medicine · doi:10.1056/nejme1111138 · Cited by 24
Laboratory monitoring of new hemostatic agents for hemophilia
Pruthi, R. K. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.10.003 · Cited by 22
“Dose modifications are based on individualized pharmacokinetics (pK) and patients’ anticipated physical activities, an approach that has been shown to reduce long-term morbidity [2].”
BackgroundThe long and short of it: using the new factor products
Dunn, A. L. (2015) · Hematology · doi:10.1182/asheducation-2015.1.26 · Cited by 27
Chowdary, P., Carcao, M. D., Holme, P. A., Jiménez‐Yuste, V., Lentz, S. R., Møss, J., Poulsen, L. H., Shen, C., Tosetto, A., Wheeler, A. P., et al. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12220 · Cited by 22
Zanon, E., Tagliaferri, A., Pasca, S., Ettorre, C. P., Notarangelo, L. D., Biasioli, C., Aru, A. B., Milan, M., Linari, S., Rocino, A., et al. (2020) · PubMed Central · doi:10.2450/2019.0040-19 · Cited by 22
Shimonishi, N., Nogami, K., Ogiwara, K., Matsumoto, T., Nakazawa, F., Soeda, T., Hirata, M., Arai, N., & Shima, M. (2020) · Haemophilia · doi:10.1111/hae.13961 · Cited by 22
Reding, M. T., Pabinger, I., Holme, P. A., Poulsen, L. H., Négrier, C., Chalasani, P., Enriquez, M. M., Wang, M., Meijer, K., Mancuso, M. E., et al. (2021) · Haemophilia · doi:10.1111/hae.14297 · Cited by 22
The Clinical Genetics of Hemophilia B (Factor IX Deficiency)
Miller, C. H. (2021) · The Application of Clinical Genetics · doi:10.2147/tacg.s288256 · Cited by 34
“Prompt treatment when bleeding occurs, termed episodic treatment, can reduce these effects; however, today’s standard of care for individuals with severe hemophilia is prophylactic treatment, providing frequent doses of factor to prevent bleeding episodes, which can reduce the longterm effects of the disease.(16) In m…”
BackgroundPatel, A. M., Corman, S. L., Chaplin, S., Raimundo, K., & Sidonio, R. F. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1669614 · Cited by 22
Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes
Croteau, S. E., Wheeler, A. P., Khan, O. A., Haley, K. M., Borst, A. J., Lattimore, S., Yeung, C. H. T., & Iorio, A. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12305 · Cited by 22
Hemophilia in the managed care setting.
Dalton, D. (2015) · PubMed · Cited by 23
Knee arthropathy: when things go wrong
Solimeno, L. P., Luck, J. J., FONDANESCHE, C., McLaughlin, P., NARAYAN, P., Sabbour, A., SOHAIL, T., & Pasta, G. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02834.x · Cited by 22
Haemophilia care – beyond the treatment guidelines
Srivastava, A. (2014) · Haemophilia · doi:10.1111/hae.12429 · Cited by 21
Vidovic, N., Musso, R., Klamroth, R., Enriquez, M. M., & Achilles, K. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.02113.x · Cited by 21
Cuesta‐Barriuso, R., Pina, J. A. L., Nieto‐Munuera, J., Sagarra‐Valls, G., Royo, J. M. P., & Torres‐Ortuño, A. (2018) · Haemophilia · doi:10.1111/hae.13444 · Cited by 21
Miracle of haemophilia drugs: Personal views about a few main players
Mannucci, P. M. (2018) · Haemophilia · doi:10.1111/hae.13519 · Cited by 21
Tiede, A., Karim, F. A., Jiménez‐Yuste, V., Klamroth, R., Lejniece, S., Suzuki, T., Groth, A., & Santagostino, E. (2020) · Haematologica · doi:10.3324/haematol.2019.241554 · Cited by 25
Fusion of engineered albumin with factor IX Padua extends half‐life and improves coagulant activity
Lombardi, S., Aaen, K. H., Nilsen, J., Ferrarese, M., Gjølberg, T. T., Bernardi, F., Pinotti, M., Andersen, J. T., & Branchini, A. (2021) · British Journal of Haematology · doi:10.1111/bjh.17559 · Cited by 24
“Prophylaxis, effectively reducing bleeding episodes and preventing joint damage, represents the standard-of-care for HB.(2) However, it requires frequent administrations, which create vein access problems and interfere with patients’ life, resulting in poor adherence to prophylactic regimens, particularly in young pat…”
BackgroundInfluentialCadé, M., Muñoz-García, J., Babuty, A., Fouassier, M., Heymann, M., Monahan, P. E., & Heymann, D. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.015 · Cited by 24
Fletcher, S. J., Jenner, K., Holland, M., & Khair, K. (2021) · Health Expectations · doi:10.1111/hex.13404 · Cited by 21
Tran, D. Q., Benson, C. C., Boice, J. A., Chitlur, M., Dunn, A. L., Escobar, M. A., Gupta, K., Johnsen, J. M., Jorgenson, J. A., Martin, S. D., et al. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2171981 · Cited by 21
“Routine prophylaxis, started at a young age and prior to the development of joint disease, dramatically reduced annualized bleeding rates (ABR) and vastly improved joint health, one of the primary morbidities of untreated hemophilia [9], for many children [10,11] and adults [12].”
BackgroundRNAi for the Treatment of People with Hemophilia: Current Evidence and Patient Selection
Boyce, S., & Rangarajan, S. (2023) · Journal of Blood Medicine · doi:10.2147/jbm.s390521 · Cited by 22
“Onset of bleeding often begins in infancy, and from early childhood recurrent spontaneous joint bleeding can develop with consequential chronic painful and disabling joint arthropathy.(2) The current standard of treatment is replacement of the deficient factor VIII or IX with recombinant or plasma-derived factors.”
Backgroundvan Bergen, E. D. P., van Leeuwen, F. H. P., Foppen, W., Timmer, M. A., Schutgens, R. E. G., Mastbergen, S. C., Lafeber, F. P. J. G., de Jong, P. A., Fischer, K., & van Vulpen, L. F. D. (2023) · Haemophilia · doi:10.1111/hae.14861 · Cited by 21
Verhagen, M. J. A., van Balen, E. C., Blijlevens, N. M. A., Coppens, M., van Heerde, W. L., Leebeek, F. W. G., Rijpma, S. R., van Vulpen, L. F. D., Gouw, S. C., & Schols, S. E. M. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.09.029 · Cited by 21
Differences between developed and developing countries in paediatric care in haemophilia
de Kleijn, P., Odent, T., Berntorp, E. E., Hilliard, P., Pasta, G., Srivastava, A., Iliescu, A., & Mohanty, S. S. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02875.x · Cited by 21
Synoviorthesis in haemophilia patients with inhibitors
Pasta, G., Mancuso, M. E., Perfetto, O. S., & Solimeno, L. P. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01890.x · Cited by 21
Gupta, S. K., Siddiqi, A.-E.-A., Soucie, J. M., Manco‐Johnson, M. J., Kulkarni, R., Lane, H. D., Ingram‐Rich, R., & Gill, J. C. (2013) · British Journal of Haematology · doi:10.1111/bjh.12267 · Cited by 21
“…reduction of bleeding episodes, improved musculoskeletal outcome and enhanced quality of life coupled with the control of treatment decisions by parents for children and adolescents in comparison to young adults (Nilsson et al, 1992; Liesner et al, 1996; Petrini, 2001; Manco-Johnson et al, 2007).”
BackgroundSelf-citationAnkle muscle activation in people with haemophilia
Kurz, E., Anders, C., Herbsleb, M., Puta, C., Czepa, D., & Hilberg, T. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02852.x · Cited by 21
How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors
Leissinger, C., Singleton, T. C., & Kruse‐Jarres, R. (2015) · Blood · doi:10.1182/blood-2014-10-551952 · Cited by 21
Self-citationSantagostino, E., Young, G. A., Carcao, M. D., Mannucci, P. M., Halimeh, S., & Austin, S. K. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2018.1419862 · Cited by 21
Von Willebrand Disease in the elderly: clinical perspectives
Chapin, J. C. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s136931 · Cited by 24
“The strategy is similar to hemophilia treatment, where factor concentrates are regularly administered to reduce joint bleeding and its associated long-term morbidity.(42,43) Symptomatology in VWD is more variable than hemophilia; joint bleeding is less common and mucosal surface bleeding can be the predominant bleedin…”
Gruppo, R. A., Malan, D. R., Kapocsi, J., Nemes, L., Hay, C. R. M., Boggio, L. N., Chowdary, P., Tagariello, G., von Drygalski, A., Hua, F., et al. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14247 · Cited by 21
Self-citationFunctional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates
Lunghi, B., Bernardi, F., Martinelli, N., Frusconi, S., Branchini, A., Linari, S., Marchetti, G., Castaman, G., & Morfini, M. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14473 · Cited by 23
“Abbreviations: Alpha, alpha rate constant associated with the distribu‐ tion phase; Alpha HL, alfa distribution half‐life; Beta, beta rate constant associated with the elimination phase; Beta HL, beta elimination half‐ life; Cl, clearance; CLD2, inter‐compartment clearance; C max, at zero time extrapolated FVIII conce…”
BackgroundInfluentialDelavenne, X., & Dargaud, Y. G. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.05.005 · Cited by 21
Kiadaliri, A., Haghparast‐Bidgoli, H., & Mamikhani, J. (2009) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462309990420 · Cited by 21
Joint Function and Arthropathy Severity in Patients with Hemophilia
Miwa, G. O. T. O., Takedani, H., Nitta, O., & KAWAMA, K. (2015) · Journal of the Japanese Physical Therapy Association · doi:10.1298/jjpta.vol18_003 · Cited by 21
Biomechanics of lower limb haemophilic arthropathy
Stephensen, D., Drechsler, W. I., & Scott, O. M. (2012) · Blood Reviews · doi:10.1016/j.blre.2012.06.003 · Cited by 22
Kurnik, K., Friedrichs, F., Halimeh, S., Krümpel, A., Bidlingmaier, C., Schobeß, R., & Nowak‐Göttl, U. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-06-0417 · Cited by 21
Factors that influence the bleeding phenotype in severe hemophilic patients
Rendo, P., Shafer, F. E., Korth-Bradley, J. M., Sivamurthy, K. M., & Korin, J. D. (2013) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e3283614210 · Cited by 23
Fogarty, P. F., & Kessler, C. M. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00004-x · Cited by 21
Sidharthan, N., Sudevan, R., Pillai, V. N., Mathew, S., Raj, M., Viswam, D., Joseph, C., & Sudhakar, A. (2017) · Haemophilia · doi:10.1111/hae.13272 · Cited by 21
Bullement, A., McMordie, S. T., Hatswell, A. J., Li, N., & Wilson, K. (2019) · PharmacoEconomics - Open · doi:10.1007/s41669-019-0158-8 · Cited by 21
Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY
Doshi, B. S., Arruda, V. R., & Arruda, V. R. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2020.069 · Cited by 25
New and improved AAVenues: current status of hemophilia B gene therapy
Brimble, M. A., Reiss, U. M., Nathwani, A. C., & Davidoff, A. M. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1106475 · Cited by 22
Novel investigations on the protective role of the FVIII / VWF complex in inhibitor development
Mannucci, P. M., Shi, Q., Bonanad, S., & Klamroth, R. (2014) · Haemophilia · doi:10.1111/hae.12465 · Cited by 20
Hermans, C. R. J. R., Mahlangu, J. N., Booth, J., Schütz, H., Santagostino, E., Young, G. A., Lee, H. ‐., Steinitz‐Trost, K. N., Blanchette, V. S., & Berntorp, E. E. (2018) · Haemophilia · doi:10.1111/hae.13483 · Cited by 20
Osteoporosis in Patients With Hemophilia: Single-Center Results From a Middle-Income Country
Şahin, S., Sadri, S., Başlar, Z., & Ar, M. C. (2019) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029619861689 · Cited by 20
“For the prevention of osteoporosis in hemophilia patients, prophylactic factor replacement therapy, calcium and vitamin D replacement, physical exercise, and quitting smoking and alcohol are recommended.(11) The aim of the present study was to investigate the impact of the bleeding disorder on bone health in patients…”
BackgroundThe Clinical Genetics of Hemophilia B (Factor IX Deficiency)
Miller, C. H. (2021) · Dove Medical Press (Taylor and Francis Group) · Cited by 20
Doshi, B. S., Samelson‐Jones, B. J., Nichols, T. C., Merricks, E. P., Siner, J. I., French, R. A., Lee, B., Arruda, V. R., & Callan, M. B. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101205 · Cited by 24
Barriers to primary prophylaxis in haemophilic children: the issue of the venous access.
Santagostino, E., & Mancuso, M. E. (2008) · PubMed Central · doi:10.2450/2008.0031-08 · Cited by 20
Plasma-derived medicines: access and usage issues.
Farrugia, A., & Cassar, J. (2012) · Europe PMC (PubMed Central) · doi:10.2450/2011.0118-11 · Cited by 19
Clinical prediction models for inhibitor development in severe hemophilia A
van den Berg, H. M., & Chalmers, E. A. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03437.x · Cited by 20
Ljung, R. C. R., Auerswald, G., Benson, G. M., Jetter, A., Jiménez‐Yuste, V., Lambert, T., Morfini, M., Remor, E., Sørensen, B., & Šalek, S. Z. (2013) · Haemophilia · doi:10.1111/hae.12094 · Cited by 20
Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa
Karpf, D. M., Sørensen, B. B., Hermit, M. B., Holmberg, H. L., Tranholm, M., Bysted, B. V., Groth, A. V., Bjørn, S. E., & Stennicke, H. R. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.02.018 · Cited by 20
“Long-term follow-up studies of patients maintained on prophylactic replacement therapy since early childhood demonstrates a significantly reduced prevalence of clinical and radiographic joint abnormalities compared with patients treated with FVIII on-demand [1] and therefore prophylaxis is currently recommended for ch…”
BackgroundImpact of aerobic exercise on haemostatic indices in paediatric patients with haemophilia
Kumar, R., Bouskill, V., Schneiderman, J. E., Pluthero, F. G., Kahr, W. H. A., Craik, A., Clark, D. S., Whitney, K., Zhang, C., Rand, M. L., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-09-0757 · Cited by 20
Aledort, L. M. (2016) · Haemophilia · doi:10.1111/hae.12970 · Cited by 20
Lanza, A. B. D. R., Álvarez, L. S., Vázquez, A. S., & Vázquez‐Casielles, R. (2016) · SpringerPlus · doi:10.1186/s40064-016-3086-4 · Cited by 28
Personalized prophylaxis in people with hemophilia A: challenges and achievements
Ar, M. C., Başlar, Z., & Soysal, T. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1252670 · Cited by 19
Garger, S. J., Severs, J. C., Regan, L. M., Hesslein, A., Ignowski, J. M., Wu, P., Long, E., Gupta, S. K., Liu, S., & Wang, W. (2016) · Haemophilia · doi:10.1111/hae.13148 · Cited by 23
Consensus Statement of the Indian Academy of Pediatrics in Diagnosis and Management of Hemophilia
Sachdeva, A., Gunasekaran, V., Ramya, H. N., Dass, J., Kotwal, J., Seth, T., Das, S., Garg, K., Kalra, M., Sirisha Rani, S., et al. (2018) · Indian Pediatrics · doi:10.1007/s13312-018-1302-8 · Cited by 23
Yada, K., & Nogami, K. (2019) · Journal of Blood Medicine · doi:10.2147/jbm.s175952 · Cited by 20
“with clotting factor concentrates (CFCs), resulting in sufficient preventions of the onset of arthropathy and significant improvements in activity of daily living (ADL) and quality of life (QOL).(4,5)”
BackgroundBenefits and limitations of extended plasma half-life factor VIII products in hemophilia A
Mannucci, P. M. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1723547 · Cited by 23
“It may appear obvious that the prevention of bleeds is preferable to their episodic treatment, but it was only after two randomized clinical trials were published in 2006 and 2011 that evidence of its effectiveness was firmly established [9,10].”
BackgroundMancuso, M. E., Oldenburg, J., Boggio, L. N., Kenet, G., Chan, A. K. C., Altisent, C., Seifert, W. F., & Santagostino, E. (2020) · Haemophilia · doi:10.1111/hae.14018 · Cited by 20
Secondary prophylaxis in adolescent and adult haemophiliacs.
Tagliaferri, A., Perna, C. D., & Rivolta, G. F. (2008) · PubMed Central · doi:10.2450/2008.0032-08 · Cited by 20
Treatment of haemophilia: building on strength in the third millennium
Mannucci, P. M. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02657.x · Cited by 20
Selective disruption of heparin and antithrombin-mediated regulation of human factor IX
Westmark, P. R., Tanratana, P., & Sheehan, J. P. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12960 · Cited by 19
Evaluating the safety of emicizumab in patients with hemophilia A
Langer, A. L., Etra, A. M., & Aledort, L. M. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1551356 · Cited by 19
Novel treatments for hemophilia through rebalancing of the coagulation cascade
Zhao, Y., Weyand, A. C., & Shavit, J. A. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.28934 · Cited by 20
Valentino, L. A., Witkop, M., Santaella, M. E. E., DiMichele, D., & Recht, M. (2022) · Haemophilia · doi:10.1111/hae.14588 · Cited by 19
Self-citationSekayan, T., Simmons, D. H., & von Drygalski, A. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2282138 · Cited by 19
“%) of FIX were deemed reasonable to reduce bleeding episodes and their associated complications [7].”
BackgroundStrilchuk, A. W., Hur, W. S., Batty, P. A., Sang, Y., Abrahams, S. R., Yong, A. S. M., Leung, J., Silva, L. M., Schroeder, J. A., Nesbitt, K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adh0027 · Cited by 22
Sternberg, A. R., Martos-Rus, C., Davidson, R. J., Liu, X., & George, L. A. (2024) · Nature Communications · doi:10.1038/s41467-024-51296-8 · Cited by 24
“The current standard-of-care is recurrent intravenous FVIII infusion or subcutaneous administration of a FVIIIa-mimetic antibody, emicizumab 4,5 .”
BackgroundProphylaxis in haemophilia B patients: unresolved issues and pharmacoeconomic implications
Santagostino, E. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02301.x · Cited by 19
Metadata
- Authors
- Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., Valentino, L. A., Hoots, W. K., Buchanan, G. R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G. A., Thompson, A. A., McRedmond, K., Soucie, J. M., Austin, H., & Evatt, B. L.
- Affiliations
- University of Colorado Denver (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-08-09
- Volume
- 357
- Issue
- 6
- Pages
- 535-544
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2167801052
- Cited by
- 1,950
- References
- 27
- Citations by year
- 2026: 57 · 2025: 70 · 2024: 98 · 2023: 115 · 2022: 106 · 2021: 123 · 2020: 127 · 2019: 110 · 2018: 114 · 2017: 107 · 2016: 123 · 2015: 116 · 2014: 131 · 2013: 116 · 2012: 112
- FWCI
- 45.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (U27/CCU812106, R00069)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hemophilia A, severe hemophilia, prophylaxis, episodic treatment, recombinant factor VIII, joint destruction, factor VIII inhibitors, joint hemorrhage, children, central venous catheter complications
- MeSH terms
- Child, Child, Preschool, Drug Administration Schedule, Factor VIII, Follow-Up Studies, Hemarthrosis, Hemophilia A, Hemorrhage, Humans, Infant, Infusions, Intravenous, Joint Diseases, Male, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.